Cargando…
Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545555/ https://www.ncbi.nlm.nih.gov/pubmed/37478166 http://dx.doi.org/10.2337/db23-0353 |
_version_ | 1785114694174900224 |
---|---|
author | Schön, Martin Zaharia, Oana P. Strassburger, Klaus Kupriyanova, Yuliya Bódis, Kálmán Heilmann, Geronimo Strom, Alexander Bönhof, Gidon J. Michelotti, Filippo Yurchenko, Iryna Möser, Clara Huttasch, Maximilian Bombrich, Maria Kelm, Malte Burkart, Volker Schrauwen-Hinderling, Vera B. Wagner, Robert Roden, Michael |
author_facet | Schön, Martin Zaharia, Oana P. Strassburger, Klaus Kupriyanova, Yuliya Bódis, Kálmán Heilmann, Geronimo Strom, Alexander Bönhof, Gidon J. Michelotti, Filippo Yurchenko, Iryna Möser, Clara Huttasch, Maximilian Bombrich, Maria Kelm, Malte Burkart, Volker Schrauwen-Hinderling, Vera B. Wagner, Robert Roden, Michael |
author_sort | Schön, Martin |
collection | PubMed |
description | Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent (1)H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO(2)max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ∼30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ∼36% and ∼62% lower compared with type 1 diabetes and control subjects, respectively. After 5 years, the M-value decreased by ∼29% in type 1 and ∼13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO(2)max. IMCL also associated with microalbuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications. ARTICLE HIGHLIGHTS: Intramyocellular lipid content (IMCL) can be elevated in insulin-resistant humans, but its dynamics and association with comorbidities remain unclear. Independently of age, sex, body mass, and skeletal muscle volume, IMCL is higher in recent-onset type 2, but not type 1 diabetes, and remains unchanged within 5 years, despite worsening insulin resistance. A degree of physical fitness modulates the association between IMCL and insulin sensitivity in type 2 diabetes. Whereas higher IMCL associates with lower insulin sensitivity in people with lower physical fitness, there is no association between IMCL and insulin sensitivity in those with higher degree of physical fitness. IMCL associates with progression of microalbuminuria, cardiovascular disease risk, and cardiac autonomic neuropathy. |
format | Online Article Text |
id | pubmed-10545555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-105455552023-10-04 Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes Schön, Martin Zaharia, Oana P. Strassburger, Klaus Kupriyanova, Yuliya Bódis, Kálmán Heilmann, Geronimo Strom, Alexander Bönhof, Gidon J. Michelotti, Filippo Yurchenko, Iryna Möser, Clara Huttasch, Maximilian Bombrich, Maria Kelm, Malte Burkart, Volker Schrauwen-Hinderling, Vera B. Wagner, Robert Roden, Michael Diabetes Pathophysiology Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent (1)H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO(2)max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ∼30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ∼36% and ∼62% lower compared with type 1 diabetes and control subjects, respectively. After 5 years, the M-value decreased by ∼29% in type 1 and ∼13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO(2)max. IMCL also associated with microalbuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications. ARTICLE HIGHLIGHTS: Intramyocellular lipid content (IMCL) can be elevated in insulin-resistant humans, but its dynamics and association with comorbidities remain unclear. Independently of age, sex, body mass, and skeletal muscle volume, IMCL is higher in recent-onset type 2, but not type 1 diabetes, and remains unchanged within 5 years, despite worsening insulin resistance. A degree of physical fitness modulates the association between IMCL and insulin sensitivity in type 2 diabetes. Whereas higher IMCL associates with lower insulin sensitivity in people with lower physical fitness, there is no association between IMCL and insulin sensitivity in those with higher degree of physical fitness. IMCL associates with progression of microalbuminuria, cardiovascular disease risk, and cardiac autonomic neuropathy. American Diabetes Association 2023-10 2023-07-21 /pmc/articles/PMC10545555/ /pubmed/37478166 http://dx.doi.org/10.2337/db23-0353 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license. |
spellingShingle | Pathophysiology Schön, Martin Zaharia, Oana P. Strassburger, Klaus Kupriyanova, Yuliya Bódis, Kálmán Heilmann, Geronimo Strom, Alexander Bönhof, Gidon J. Michelotti, Filippo Yurchenko, Iryna Möser, Clara Huttasch, Maximilian Bombrich, Maria Kelm, Malte Burkart, Volker Schrauwen-Hinderling, Vera B. Wagner, Robert Roden, Michael Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes |
title | Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes |
title_full | Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes |
title_fullStr | Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes |
title_full_unstemmed | Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes |
title_short | Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes |
title_sort | intramyocellular triglyceride content during the early course of type 1 and type 2 diabetes |
topic | Pathophysiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545555/ https://www.ncbi.nlm.nih.gov/pubmed/37478166 http://dx.doi.org/10.2337/db23-0353 |
work_keys_str_mv | AT schonmartin intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT zahariaoanap intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT strassburgerklaus intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT kupriyanovayuliya intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT bodiskalman intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT heilmanngeronimo intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT stromalexander intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT bonhofgidonj intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT michelottifilippo intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT yurchenkoiryna intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT moserclara intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT huttaschmaximilian intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT bombrichmaria intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT kelmmalte intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT burkartvolker intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT schrauwenhinderlingverab intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT wagnerrobert intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT rodenmichael intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes AT intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes |